Hero Biopharma
Karius Laboratory Service for Pathogen Biomarker Detection
Precision medicine lab service to drive efficiency in biopharmaceutical clinical development
Karius offers pathogen biomarker detection as a lab service to biopharmaceutical companies. Our technology is based on next-generation sequencing of microbial cell-free DNA in plasma.
Partnering with Karius can help accelerate your clinical trials in a number of ways, including identification of difficult-to-detect pathogens with a rapid turnaround time, quantitative monitoring of pathogen DNA on therapy, and direct detection in plasma of potential co-infections.
Problem
- Current tests detect only one or a small panel of pathogens.
- Testing for a range of pathogens with multiple assays is expensive and time-consuming.
- Patients may be enrolled into studies based on presumed clinical infection rather than on direct microbiologic confirmation.
Karius Laboratory Service
A plasma-based next-generation sequencing test that can rapidly identify more than a thousand pathogens from a single blood draw.
Precise, broad-based detection of bacteria, DNA viruses, fungi/molds, and protozoa.
CLIA-certified, CAP-accredited clinical laboratory with dedicated program and data management support.
Clinical Trial Applications
Rapid detection and monitoring of pathogens may be useful in these and other clinical trial scenarios:
- Potential selection of eligible subjects
- Monitoring drug efficacy
- Coding and adjudication of adverse events
- Assisting with determination of dosing and duration of treatment
- Identification of co-infections that could impact therapeutic efficacy, safety and adverse event reporting
For more information or to discuss pathogen biomarker detection in your clinical trials, please contact us at biopharma@kariusdx.com.
For additional publications, abstracts, and clinical trials, visit www.kariusdx.com/clinical-data.
Enter your email to download our biopharma flyer: